“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

We spoke with Dr Kellan Baker of the Whitman-Walker institute to shed some light on the many changes taking place to various aspects of medical care for LGBTQ+ individuals.

The approval was supported by pooled data from 2 open-label, single arm trials: the phase 2 NI-0501-06 study and the phase 3 EMERALD trial.

Children younger than 6 years of age who are prescribed extended-release stimulants for attention-deficit hyperactivity disorder (ADHD) may experience ...

The wearable, transcutaneous neurostimulation device delivers personalized therapy using a proprietary AI algorithm.

An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...

Gammagard Liquid ERC is a ready-to-use formulation with low IgA content designed to ease administration burden by removing the need to reconstitute.

Linear relationship seen for waist circumference, BP; reduction in HOMA-IR, hemoglobin A1c seen with modest weight reduction.

HealthDay News — Attention-deficit/hyperactivity disorder (ADHD) medications remain associated with a reduced risk for various real-world outcomes, but the magnitude of these associations decreases ...

Wristband that provides relief for upper limb tremor is approved; FDA warns of clinically significant weight loss in younger kids taking ADHD meds; REMS removed for CAR T-cell immunotherapies; ...

The Children’s Health Defense sued Meta Platforms, the parent company of Facebook and Instagram. It claimed the company removed their content in violation of free speech rights, NBC News reported.